17,261 trials
Autistic Disorder · Asperger Syndrome · Autism Spectrum Disorder
Primary: Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks — 7.6; -0.6 units on a scale
Metastatic Melanoma
Primary: Progression-free Survival (PFS) — 4.04 Months
Coronary Artery Disease
Primary: In-Stent Late Lumen Loss — 0.27; 0.58 mm
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Typhoid Fever
Primary: Anti-Vi ELISA Geometric Mean Concentration (GMC) — 35; 31; 3.22 ELISA Units/mL
Periodontitis · Gingivitis · Inflammation
Primary: Change in Pocket Depth (mm) — -0.71; -0.54 mm — p=<0.05
Lung Cancer · Non-Small Cell Lung Cancer
Primary: Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1 — 0.75; 1.0; 0.75; 1.5 hours
Substance Abuse · HIV Infections
Primary: To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals. — 44…
Pain
Primary: Change in Pain — 1.14; 3.5 units on a scale
Bronchiectasis
Primary: Reliability of the Respiratory Domain of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) — 0.80 Intraclass Correlation Coefficient
Schizophrenia
Primary: Positive and Negative Symptom Scale (PANSS) Total Score at Baseline — 94.74; 94.24; 96.88; 101.33 units on a scale
Hematological Malignancies
Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants
HIV-1 Infection
Primary: The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip — -1.46; -3.19 percentage change — p=0.001
Leiomyosarcoma
Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants
Parkinson's Disease
Primary: Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. — 126; 112; 17; 12 participants